Tumor-infiltrating lymphocytes

Grit Biotechnology Completes Series A+ Financing to Accelerate Development of its Tumor Infiltrating Lymphocyte (TIL) Therapy Pipeline

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Health sciences, Life sciences, Oncology, Cell biology, Lymphocytes, Tumor-infiltrating lymphocytes, Therapy, Cell therapy, Iovance Biotherapeutics

SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.

Key Points: 
  • SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.
  • It is on track to bring the first TIL therapy to solid tumor patients in China.
  • The funds raised will help Grit advance its lead program into the clinic and support the development of its rich preclinical pipeline.
  • Grit Bio is a leading Chinese cell therapy company founded by cell therapy experts from Duke University and University of Southern California in 2019.

Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Retrieved on: 
Sunday, June 6, 2021
Clinical medicine, Medicine, Cancer treatments, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Pembrolizumab, Melanoma, Programmed cell death protein 1

The data were presented in an oral presentation at the ASCO 2021 Annual Meeting .

Key Points: 
  • The data were presented in an oral presentation at the ASCO 2021 Annual Meeting .
  • The long-term follow-up data for Cohort 2 in the C-144-01 clinical study continue to demonstrate durability and depth of lifileucel TIL therapy response.
  • Title: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.
  • ET to discuss ASCO clinical data updates for lifileucel alone and in combination with pembrolizumab in patients with advanced melanoma.

AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medical specialties, Medicine, Oncology, Immune system, Cancer immunotherapy, Lymphocytes, Tumor-infiltrating lymphocytes, Breast cancer, Cancer, Checkpoint inhibitor, Lung cancer

The software analyzes tumor-infiltrating lymphocytes(TIL) in cancer patients' tissue slides, assigning a score to each criterion.

Key Points: 
  • The software analyzes tumor-infiltrating lymphocytes(TIL) in cancer patients' tissue slides, assigning a score to each criterion.
  • Lunit has been validating the clinical application of Lunit SCOPE IO for predicting ICI treatment outcomes in advanced lung cancer.
  • According to this study, unique parenchymal pattern with future breast cancer risk among breast cancer patients was identified by AI.
  • Title: Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.

Instil Bio to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, June 1, 2021
Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Health care, Iovance Biotherapeutics, Clinical medicine, Health

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 9:30 a.m.

Key Points: 
  • DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 9:30 a.m.
  • A live webcast of the presentation may be accessed at: https://wsw.com/webcast/jeff174/til/1707183 or by visiting the News & Events section of the Instil Bio website at www.instilbio.com .
  • Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer.
  • Instil has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies.

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Medicine, Clinical medicine, Medical specialties, Oncology, Virotherapy, Lymphocytes, Tumor-infiltrating lymphocytes, Immunotherapy, Melanoma, Iovance Biotherapeutics, Cancer, Metástasis

b'Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.

Key Points: 
  • b'Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.
  • TIL cells are extracted from a patient\xe2\x80\x99s own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.

MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors

Retrieved on: 
Monday, May 17, 2021
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, Articles, Clinical medicine, Branches of biology, Biotechnology, Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Cancer immunotherapy, Immunotherapy, Synthetic biology, Refuge Biotechnologies, MD Anderson, REFUGE BIOTECHNOLOGIES, MD ANDERSON

b'Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors.

Key Points: 
  • b'Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors.
  • View the full release here: https://www.businesswire.com/news/home/20210517005116/en/\nUnder the agreement, MD Anderson will possess exclusive rights to apply Refuge\xe2\x80\x99s proprietary platform for next-generation cell engineering to its tumor infiltrating lymphocyte (TIL) programs.
  • With a state-of-the-art GMP cell therapy manufacturing facility, the platform unites MD Anderson research with industrial therapeutic development.\nRefuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005116/en/\n'

Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Health, Life sciences, Instil, Tumor-infiltrating lymphocytes, Melanoma, Orphan drug, Til

b'Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168\nDALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (\xe2\x80\x9cInstil\xe2\x80\x9d) (NASDAQ: TIL), a clinical-stage biopharmaceutical company developing tumor infiltrating lymphocytes, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2021 financial results and provided a corporate update.\n\xe2\x80\x9cIn March of 2021, Instil completed an initial public offering to support the development of our TIL therapies.

Key Points: 
  • b'Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168\nDALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (\xe2\x80\x9cInstil\xe2\x80\x9d) (NASDAQ: TIL), a clinical-stage biopharmaceutical company developing tumor infiltrating lymphocytes, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2021 financial results and provided a corporate update.\n\xe2\x80\x9cIn March of 2021, Instil completed an initial public offering to support the development of our TIL therapies.
  • \xe2\x80\x9cWe recently presented clinical data from our compassionate use program at the AACR conference and received orphan drug designation from the U.S. Food and Drug Administration for ITIL-168 in melanoma.
  • The gross proceeds of the offering were $368 million, before underwriting discounts and commissions and other offering expenses payable by Instil.
  • Instil also expects U.S. clinical manufacturing to be online in the first half of 2022.\nAs of March 31, 2021, cash and cash equivalents totaled $609.6 million, compared to $241.7 million as of December 31, 2020.

Iovance Biotherapeutics to Present at Upcoming Conferences

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Medicine, Clinical medicine, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Immune system, Melanoma, Iovance Biotherapeutics, Cancer, Lymphocyte, Metástasis

Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.

Key Points: 
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.
  • TIL cells are extracted from a patient\xe2\x80\x99s own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.
  • Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

Tumor Infiltrating Lymphocytes TIL Immunotherapy Clinical Trials Therapy Companies Insight 2025

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Immunotherapy, Iovance Biotherapeutics

b'NEW DELHI, April 29, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:\nTumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies\nExpected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000\nThis Report is bases upon the combinational approach of secondary and primary research which is further backed up by access to open and paid up databases.

Key Points: 
  • b'NEW DELHI, April 29, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:\nTumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies\nExpected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000\nThis Report is bases upon the combinational approach of secondary and primary research which is further backed up by access to open and paid up databases.
  • The company financial reports, quarterly disclosures, company news, market updates, industry journal\'s, drug clinical updates and drug sales releases are used as the fundamental premise for all the market estimates, patent insight, clinical approved dosage information and other data indicators encapsulated in "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" report.
  • It is believed that the blockbuster model of drugs develop under TIL therapy will be driving the shareholder value in the upcoming years.
  • The numerous trends and growing opportunities associated with the market is also leading towards improving health care department by promoting research activities for TIL therapy.

Tumor Infiltrating Lymphocytes TIL Immunotherapy Clinical Trials Therapy Companies Insight 2025

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Immunotherapy, Iovance Biotherapeutics

b'NEW DELHI, April 29, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:\nTumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies\nExpected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000\nThis Report is bases upon the combinational approach of secondary and primary research which is further backed up by access to open and paid up databases.

Key Points: 
  • b'NEW DELHI, April 29, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:\nTumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies\nExpected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000\nThis Report is bases upon the combinational approach of secondary and primary research which is further backed up by access to open and paid up databases.
  • The company financial reports, quarterly disclosures, company news, market updates, industry journal\'s, drug clinical updates and drug sales releases are used as the fundamental premise for all the market estimates, patent insight, clinical approved dosage information and other data indicators encapsulated in "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" report.
  • It is believed that the blockbuster model of drugs develop under TIL therapy will be driving the shareholder value in the upcoming years.
  • The numerous trends and growing opportunities associated with the market is also leading towards improving health care department by promoting research activities for TIL therapy.